54 citations
,
May 2019 in “Multiple Sclerosis and Related Disorders” Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” Baricitinib effectively treats severe alopecia for up to 104 weeks.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
2 citations
,
May 2025 in “Frontiers in Pharmacology” Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.
January 2026 in “Frontiers in Bioscience-Landmark” Araliadiol protects skin cells from damage by boosting antioxidant defenses.
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
1 citations
,
November 2015 in “Cochrane library” 5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
3 citations
,
May 2024 in “Journal of Drug Delivery and Therapeutics” Aftimoon has potential health benefits for various diseases and could be integrated into modern healthcare.
July 2025 in “Journal of Investigative Dermatology” AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
1 citations
,
November 2024 in “Expert Opinion on Drug Safety” Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
21 citations
,
January 2010 in “JOURNAL OF HEALTH SCIENCE” Abietic acid from pine resin can effectively inhibit testosterone 5α-reductase.
September 2016 in “Journal of the Society of Cosmetic Scientists of Korea” Pine resin and abietic acid were found to promote hair growth in mice.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
15 citations
,
September 2018 in “Indian Research Journal of Pharmacy and Science” Aromatherapy uses essential oils to improve mood and well-being.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
January 2026 in “Journal of the American Academy of Dermatology” This retrospective cohort study using the TriNetX network investigated the potential risk of osteoporosis or osteopenia in women with androgenetic or frontal fibrosing alopecia treated with 5-alpha reductase inhibitors (5-ARIs), such as finasteride and dutasteride. Despite theoretical concerns that these treatments could negatively impact bone mineral density due to their mechanism of reducing dihydrotestosterone, the study found no elevated risk for osteoporosis or osteopenia among the women treated with 5-ARIs. This finding provides important evidence for the skeletal safety of long-term 5-ARI therapy in women, addressing a significant knowledge gap and supporting evidence-based prescribing practices.